Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Maryia Zhdanava, Zhijie Ding, Ameur M. Manceur, Erik Muser, Patrick Lefebvre, Christopher Holiday, Marie-Hélène Lafeuille & Dominic Pilon. (2023) Treatment persistence among bio-naïve patients with Crohn’s disease initiated on ustekinumab or adalimumab. Current Medical Research and Opinion 39:4, pages 533-543.
Read now
Read now
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Giuseppe Costantino, Marco Muscianisi, Maria Cappello, Laura Guida, Enrica Giuffrida, Antonio Magnano, Dario Pluchino, Concetta Ferracane, Giovanni Magrì, Roberto Di Mitri, Filippo Mocciaro, Antonino Carlo Privitera, Salvatore Camilleri, Serena Garufi, Sara Renna, Angelo Casà, Barbara Scrivo, Marco Ventimiglia & Ambrogio Orlando. (2020) Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Expert Opinion on Biological Therapy 20:11, pages 1381-1384.
Read now
Read now
Fabio Salvatore Macaluso, Marcello Maida, Marco Ventimiglia, Mario Cottone & Ambrogio Orlando. (2020) Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies. Expert Opinion on Biological Therapy 20:2, pages 193-203.
Read now
Read now
Articles from other publishers (26)
Dinakar Swastha, Nambolan Varsha, Suresh Aravind, Kavassery Balasubramanian Samyuktha, Muruganandam Mohaneswari Yokesh, Akshad Balde, Bakthavatchalam Loganathan Ayilya, Soottawat Benjakul, Se-Kwon Kim & Rasool Abdul Nazeer. (2023) Alginate-based drug carrier systems to target inflammatory bowel disease: A review. International Journal of Biological Macromolecules 244, pages 125472.
Crossref
Crossref
Jinjing Liu, Xin Yu, Zhimian Wang, Weiwei Liu, Xiaochuan Liu, Xiaoou Wang, Menghao Zhang, Yan Zhao, Fengchun Zhang, Hong Yang & Wenjie Zheng. (2023) Baricitinib for the treatment of intestinal Behçet's disease: A pilot study. Clinical Immunology 247, pages 109241.
Crossref
Crossref
Lingna Li, Ke Jiang, Dandi Lou, Mengting Zhang, Yetan Shi, Jingyi Shen & Xiaojun Fu. (2023) Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn’s Disease Patients. European Surgical Research, pages 412-421.
Crossref
Crossref
Federica Crispino, Mauro Grova, Erica Maria Bruno, Noemi Monachino, Giuseppe Rizzo, Angelo Casà, Sara Renna, Fabio Salvatore Macaluso & Ambrogio Orlando. (2022) Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets. Drugs 82:11, pages 1151-1163.
Crossref
Crossref
Philip Esters, Christopher Hackenberg, Herrmann Schulze & Axel U. Dignass. (2022) Biologika bei chronisch-entzündlichen DarmerkrankungenBiologics in inflammatory bowel diseases. Der Internist 63:2, pages 155-164.
Crossref
Crossref
Angelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli & Matteo Megna. (2021)
Real world practice indirect comparison between guselkumab and risankizumab: Results from an
Italian
retrospective study
. Dermatologic Therapy 35:1.
Crossref
Crossref
A. A. Hotko, M. Yu. Pomazanova & M. V. Durleshter. (2021) Diseases of cardiovascular system in patients with moderate-to-severe and severe forms of psoriasis. Medical alphabet:34, pages 35-38.
Crossref
Crossref
Mohammad Shehab, Fatema Alrashed, Ahmad Alfadhli, Khazna Alotaibi, Abdullah Alsahli, Hussain Mohammad, Preethi Cherian, Irina Al-Khairi, Thangavel Alphonse Thanaraj, Arshad Channanath, Hamad Ali, Mohamed Abu-Farha, Jehad Abubaker & Fahd Al-Mulla. (2021) Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies. Vaccines 9:12, pages 1471.
Crossref
Crossref
Katarzyna Pawlak-Buś, Wiktor Schmidt & Piotr Leszczyński. (2021) Lack of Association between Serum Interleukin-23 and Interleukin-27 Levels and Disease Activity in Patients with Active Systemic Lupus Erythematosus. Journal of Clinical Medicine 10:20, pages 4788.
Crossref
Crossref
Feras M. Ghazawi, Farhan Mahmood, Leon Kircik, Yves Poulin, Marc Bourcier, Ronald Vender, Marni C. Wiseman, Charles Lynde & Ivan V. Litvinov. (2021) A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. Frontiers in Medicine 8.
Crossref
Crossref
Kibrom M. Alula, Dakota N. Jackson, Andrew D. Smith, Daniel S. Kim, Kevin Turner, Elizabeth Odstrcil, Benny A. Kaipparettu, Themistocles Dassopoulos, K. Venuprasad, Linda A. Feagins & Arianne L. Theiss. (2021) Targeting Mitochondrial Damage as a Therapeutic for Ileal Crohn’s Disease. Cells 10:6, pages 1349.
Crossref
Crossref
Ewa Żyła, Katarzyna Dziendzikowska, Dariusz Kamola, Jacek Wilczak, Rafał Sapierzyński, Joanna Harasym & Joanna Gromadzka-Ostrowska. (2021) Anti-Inflammatory Activity of Oat Beta-Glucans in a Crohn’s Disease Model: Time- and Molar Mass-Dependent Effects. International Journal of Molecular Sciences 22:9, pages 4485.
Crossref
Crossref
Louisa Nitsch, Linda Schneider, Julian Zimmermann & Marcus Müller. (2021) Microglia-Derived Interleukin 23: A Crucial Cytokine in Alzheimer's Disease?. Frontiers in Neurology 12.
Crossref
Crossref
Kevin Yang, Allen S. W. Oak & Boni E. Elewski. (2020) Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. American Journal of Clinical Dermatology 22:2, pages 173-192.
Crossref
Crossref
Ki-Uk Kim, Jisu Kim, Wan-Hoon Kim, Hyeyoung Min & Chang Hwan Choi. (2021) Treatments of inflammatory bowel disease toward personalized medicine. Archives of Pharmacal Research 44:3, pages 293-309.
Crossref
Crossref
Martina Franzin, Katja Stefančič, Marianna Lucafò, Giuliana Decorti & Gabriele Stocco. (2021) Microbiota and Drug Response in Inflammatory Bowel Disease. Pathogens 10:2, pages 211.
Crossref
Crossref
Fabio Salvatore Macaluso, Marcello Maida, Mauro Grova, Federica Crispino, Giulia Teresi, Adele Orlando & Ambrogio Orlando. (2021) Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. Therapeutic Advances in Gastroenterology 14, pages 175628482110106.
Crossref
Crossref
Fabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, Anna Viola, Aldo Sitibondo, Maria Cappello, Barbara Scrivo, Anita Busacca, Antonino Carlo Privitera, Salvatore Camilleri, Serena Garufi, Roberto Di Mitri, Filippo Mocciaro, Nunzio Belluardo, Emiliano Giangreco, Carmelo Bertolami, Sara Renna, Rosalba Orlando, Giulia Rizzuto, Mario Cottone & Ambrogio Orlando. (2020) A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. Journal of Gastroenterology and Hepatology 36:1, pages 105-111.
Crossref
Crossref
Angelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli & Matteo Megna. (2020)
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐
interleukin
‐17 treatment: A real‐life 52‐week retrospective study
. Dermatologic Therapy 34:1.
Crossref
Crossref
Bergithe E. Oftedal & Anette S. B. Wolff. (2020) New era of therapy for endocrine autoimmune disorders. Scandinavian Journal of Immunology 92:5.
Crossref
Crossref
P. A. Makarchuk, E. Yu. Lomakina & E. A. Belousova. (2020) Ustekinumab in patients with Crohn’s disease with extraintestinal manifestations (psoriasis). Meditsinskiy sovet = Medical Council:15, pages 121-126.
Crossref
Crossref
Audrey Seamons, Michael Haenisch, Stacey Meeker, Olesya Pershutkina, Thea Brabb, Piper M. Treuting & Jisun Paik. (2020) Protective Effects of ALDH1A Enzyme Inhibition on Helicobacter-Induced Colitis in Smad3−/− Mice are Associated with Altered α4ß7 Integrin Expression on Activated T Cells. Nutrients 12:10, pages 2927.
Crossref
Crossref
Fabio Salvatore Macaluso & Iago Rodríguez-Lago. (2020) JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. Current Drug Metabolism 21:4, pages 247-255.
Crossref
Crossref
C.A. Shaw, L.C.S. Kole & B.E. Elewski. (2019) Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy. Journal of the European Academy of Dermatology and Venereology 33:11.
Crossref
Crossref
Nitin Tandra, Peipei Wu, Xinyuan Hu, Fei Mao, Wenrong Xu & Hui Qian. (2019) Extracellular Vesicles: A New Nano Tool for the Treatment of Inflammatory Bowel Diseases. Current Nanoscience 15:6, pages 589-595.
Crossref
Crossref
E. L. Nasonov & A. M. Lila. (2019) Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Rheumatology Science and Practice 57:1, pages 8-16.
Crossref
Crossref